Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Concept/Terms
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in Harvard Catalyst Profiles by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 123 | 123 |
1995 | 0 | 131 | 131 |
1996 | 0 | 133 | 133 |
1997 | 0 | 112 | 112 |
1998 | 0 | 121 | 121 |
1999 | 1 | 163 | 164 |
2000 | 2 | 182 | 184 |
2001 | 0 | 244 | 244 |
2002 | 0 | 246 | 246 |
2003 | 0 | 261 | 261 |
2004 | 1 | 300 | 301 |
2005 | 0 | 309 | 309 |
2006 | 0 | 281 | 281 |
2007 | 1 | 281 | 282 |
2008 | 2 | 278 | 280 |
2009 | 0 | 265 | 265 |
2010 | 2 | 253 | 255 |
2011 | 1 | 256 | 257 |
2012 | 0 | 262 | 262 |
2013 | 0 | 224 | 224 |
2014 | 0 | 262 | 262 |
2015 | 0 | 234 | 234 |
2016 | 3 | 242 | 245 |
2017 | 4 | 286 | 290 |
2018 | 2 | 239 | 241 |
2019 | 0 | 207 | 207 |
2020 | 0 | 180 | 180 |
2021 | 4 | 117 | 121 |
2022 | 0 | 18 | 18 |
2023 | 0 | 7 | 7 |
2024 | 0 | 1 | 1 |
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
A Single-Blind, Placebo Controlled Trial of Triple Beaded Mixed Amphetamine Salts in DSM-5 Adults With ADHD Assessing Effects Throughout the Day. J Atten Disord. 2024 Mar; 28(5):810-819.
-
Effects of cannabinoid agonists and antagonists in male rats discriminating the synthetic cannabinoid AM2201. Eur J Pharmacol. 2023 Dec 05; 960:176168.
-
Antinociceptive Agents as General Anesthetic Adjuncts: Supra-additive and Infra-additive Interactions. Anesth Analg. 2023 Dec 01; 137(6):1198-1207.
-
Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study. J Clin Psychiatry. 2023 Oct 09; 84(6).
-
CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome. Stat Med. 2023 06 30; 42(14):2409-2419.
-
A Phase I, Double-blind, Randomized, Placebo-controlled, Single Dose-escalation Study to Evaluate the Tolerability, and Safety of Cytisinicline in Adult Smokers. Nicotine Tob Res. 2023 03 22; 25(4):814-820.
-
A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemother Pharmacol. 2023 04; 91(4):291-300.
-
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day. J Child Adolesc Psychopharmacol. 2023 02; 33(1):14-19.
-
The past, present, and future of chemotherapy with a focus on individualization of drug dosing. J Control Release. 2022 Dec; 352:840-860.
-
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial. Psychiatry Res. 2022 Dec; 318:114922.